Compare Genuine Parts Company (GPC) vs TransMedics Group Inc (TMDX) Price & Performance

GPC trades at $134.54, down 0.8% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings with EPS of $2.15 beating estimates of $2.08, while revenue grew 6% year-over-year to $6.5 billion. However, net income margin remains thin at 0.13% for 2025, though the P/S ratio of 0.75 suggests reasonable valuation relative to sales.

The stock offers a dividend yield supported by 70 years of increases, with analyst consensus target at $148.67 suggesting 10.5% upside. Key risks include compressed profit margins, rising debt levels, and sensitivity to automotive industry cycles. Institutional ownership shows mixed signals with some funds increasing positions while others trimmed holdings in Q1 2026.

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.